Abstract 897P
Background
The early response to concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) is closely correlated with prognosis. In this study, we aimed to predict early response using a combined model that combines sub-regional radiomics features from multi-sequence MRI with clinically relevant factors.
Methods
A total of 104 patients with LA-NPC were randomly divided into training and validation cohorts at a ratio of 3:1. Radiomic features were extracted from subregions within the tumor area using the K-means clustering method, and feature selection was performed using LASSO regression. Four models were established: classical radiomics model, clinical medol, Intratumor Heterogeneity (ITH) score-based model and a fusion model combining ITH score with clinical factors. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
Results
Among the models, the combined model incorporating ITH score and clinical factors demonstrated the highest predictive performance in the test cohort (AUC = 0.838). Additionally, the models based on ITH score showed superior prognostic value in both the training cohort (AUC = 0.888) and the test cohort (AUC = 0.833).
Conclusions
The combined model that integrates the ITH score with clinical factors exhibited superior performance in predicting early response following concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
Clinical trial identification
Editorial acknowledgement
The authors would like to thank Yuandong Cao, Weilin Xu, and Shu Zhou for their valuable comments and discussions. We also express their gratitude to Jinling Yuan and Mengxing Wu for their assistance with data analysis. This work was supported by the Jiangsu Province Doctoral Start-up Foundation for Entrepreneurship and Innovation (Grant No. 2019303073386ER19) and the Clinical Competence Enhancement Project of Jiangsu Provincial People's Hospital (Grant No. JSPH-MC-2021-17).
Legal entity responsible for the study
The First Affiliated Hospital of Nanjing Medical University.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
751P - Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial
Presenter: Carol Aghajanian
Session: Poster session 02
752P - Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival
Presenter: Tibor Zwimpfer
Session: Poster session 02
753P - Unlocking the circulating immune landscape of advanced clear-cell ovarian cancer: Insights from the MOCCA trial
Presenter: Felix Blanc-Durand
Session: Poster session 02
754P - Initial results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
Presenter: Ronnie Shapira-Frommer
Session: Poster session 02
755P - Beyond HRD status: Unraveling genetic variants impacting PARP inhibitor sensitivity in advanced ovarian cancer
Presenter: Maj Kamille Kjeldsen
Session: Poster session 02
756P - Final analysis of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
Presenter: Junsik Park
Session: Poster session 02
757P - Sustained long-term responders to niraparib maintenance in recurrent platinum-sensitive high-grade ovarian cancer (PSROC): A subanalysis of the GEICO-88R study
Presenter: Juan Cueva Banuelos
Session: Poster session 02
758P - Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients
Presenter: Emese Zsiros
Session: Poster session 02
759P - JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies
Presenter: Qunxian Rao
Session: Poster session 02
760P - Cadonilimab with neoadjuvant chemotherapy in advanced ovarian cancer patients (AK104-IIT-003): An open, prospective, single arm, phase II trial
Presenter: Jie Tang
Session: Poster session 02